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Abstract
Background: Achieving consensus from a range of relevant stakeholders about an agreed set of core outcomes to be
measured and reported as a minimum in clinical trials has the potential to enhance evidence synthesis and make findings
more relevant and applicable. Intervention research to improve outcomes for young adults with type 1 diabetes (T1DM)
is hampered by inconsistent use of outcome measures. This population frequently struggles to manage their condition
and reports suboptimal clinical outcomes. Our aim was to conduct an international, e-Delphi consensus study to identify
a core outcome set (COS) that key stakeholders (young adults with T1DM, diabetes health professionals, diabetes
researchers and diabetes policy makers) consider as essential outcomes for future intervention research.
Methods: Using a list of 87 outcomes generated from a published systematic review, we administered two online
surveys to a sample of international key stakeholders. Participants in the first survey (survey 1; n = 132) and the second
survey (survey 2; n= 81) rated the importance of the outcomes. Survey 2 participants received information on total mean
rating for each outcome and a reminder of their personal outcome ratings from Survey 1. Survey 2 results were discussed
at a consensus meeting and participants (n = 12: three young adults with T1DM, four diabetes health professionals, four
diabetes researchers and one diabetes policy maker) voted on outcomes. Final core outcomes were included provided
that 70% of consensus group participants voted for their inclusion.
Results: Eight core outcomes were agreed for inclusion in the final COS: measures of diabetes-related stress;
diabetes-related quality of life; number of severe hypoglycaemic events; self-management behaviour; number
of instances of diabetic ketoacidosis (DKA); objectively measured glycated haemoglobin (HbA1C); level of clinic
engagement; and perceived level of control over diabetes.
Conclusions: This study is the first to identify a COS for inclusion in future intervention trials to improve
outcomes for young adults with T1DM. Use of this COS will improve the quality of future research and
increase opportunities for evidence synthesis. Future research is necessary to identify the most robust
outcome measure instruments.
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Background
Type 1 diabetes (T1DM) requires intensive self-monitoring
of blood glucose and self-management, including adminis-
tering insulin, regulating diet and exercise, to maintain
optimal glycaemic control [1]. Young adults, aged 15–30
years, are one group of individuals consistently identified as
being at higher risk of disengagement from diabetes self-
management and adherence to diabetes medication [2].
Young adults have been identified as being at higher risk
than other groups of suboptimal glycaemic control [3] and
higher incidence of ketoacidosis (DKA) [4]. Young adult-
hood is often a time of transition during which diabetes
self-management can be particularly difficult, with common
lifestyle challenges including moving away from the family
home for the first time, beginning employment or univer-
sity, and transitioning from paediatric to adult healthcare
services [5, 6].
Effective interventions to improve self-management
and outcomes for young adults with T1DM are needed.
Systematic reviews of interventions have suggested that
there have been relatively few trials and the quality of
this research is often low [5, 7]. Furthermore, evidence
synthesis within systematic reviews is hampered by the
use of diverse outcomes and measures across interven-
tion studies [7].
Within clinical trials research, there is growing aware-
ness that insufficient attention has been paid to what out-
come measures are selected [8]. Frequently, trials do not
include outcomes which are considered most important
to young adults and professionals making decisions about
healthcare, limiting the relevance and applicability of
research. In addition, synthesizing evidence from trials to
determine the most effective interventions is frequently
hampered by heterogeneity in outcome measurement [9].
To address this problem, trialists advocate the identifi-
cation of core outcome sets (COS), defined as agreed
standardised collections of outcomes which should be
measured and reported in all trials, for specific clinical
areas [10]. Such COS are considered to be a minimum
set of outcomes, which should be measured and re-
ported in all trials. The involvement of key stakeholders,
including patients, the public and healthcare profes-
sionals, in the identification of COS can ensure that out-
comes are relevant to all stakeholder groups [9].
Previous COS studies with patients or the public have
identified outcomes that were not previously identified
by other stakeholders [11]. The COMET (Core Outcome
Measures in Effectiveness Trials) Initiative (see: http://
comet-initiative.org/) brings together people interested
in the development and application of agreed standar-
dised sets of outcomes, which has led to a growing num-
ber of published COS studies [12–18]. No COS has yet
been produced for clinical trials of interventions for
young adults with T1DM.
The aim of this study was to identify a COS for inter-
vention trials aiming to improve clinical, behavioural or
psychosocial outcomes for young adults with T1DM. A
recent review of such interventions reported a wide range
of different outcomes being used across trials and recom-
mended the development of a COS for future research [7].
We have conducted and reported our COS study in
accordance with recently published guidelines [8].
Methods
We conducted an international, multi-perspective Delphi
consensus study, which involved three phases: (1) gener-
ation of a list of all possible relevant outcomes; (2) an elec-
tronic Delphi survey, which contained two rounds; and (3)
a consensus meeting to agree a final COS. A Delphi study
involves several sequential rounds of data collection and
analysis in order to collate the opinions of participants
into a group consensus on a particular topic. After each
round, responses are analysed and redistributed to partici-
pants for further comment in successive rounds [12].
Ethical approval was granted from the University Research
Ethics Committee on 29 January 2016 (ref: CA1427).
Participants
Participants were recruited using multiple routes. Young
adults with T1DM (aged 15–30 years), diabetes health
professionals, diabetes researchers and policy makers in
diabetes services were included to ensure that our COS
was comprehensive and clinically relevant. The inter-
national research team facilitated the recruitment
process, by distributing the study invite via email to lists
of diabetes researchers, health professionals and policy
networks to which they had access. Young adults with
T1DM were invited via support groups, diabetes services
or through other methods accessible to members of the
study team. For example, in Ireland, the study invite was
circulated to Diabetes Ireland, a national charity dedi-
cated to supporting and educating people with diabetes.
The study was more widely announced via social media
channels, for example, invitations were posted on Face-
book accounts of online support groups for people with
T1DM. Snowball sampling was used and participants
were invited to convey the study details to other individ-
uals who may have relevant expertise to participate in
the study.
The invitation email included information about the
study aims, methods and research team, and a link to
the survey. Informed consent was obtained from each
participant upon online registration for the survey, by
providing participant information and requesting that
participants indicate consent by clicking on the consent
box. The importance of completing both rounds of the
survey was emphasised and generic reminder emails
were distributed to round 1 participants to increase
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completion of round 2. A unique identifier was assigned
to each participant tracked to their email address which
allowed linkage of participants in rounds 1 and 2. The
study information text used to introduce Surveys 1 and
2 can be seen in the Additional file 1.
Phase 1: Generation of a list of all possible relevant
outcomes
An initial list of possible relevant outcomes was gener-
ated from a previously conducted systematic review of
interventions to improve clinical, behavioural or psycho-
social outcomes for young adults (aged 15–30 years)
with T1DM [7]. This list was reviewed and discussed by
the research team and outcomes were collapsed where
possible to create a list of distinct outcomes. The team
also had the opportunity to suggest any additional out-
come measures they thought were potentially important
but not included in the list. A final list of 87 outcomes
was agreed upon.
Phase 2: Electronic Delphi survey
The Delphi surveys were created using SurveyMethods
online survey software (https://www.surveymethods.-
com/). The surveys were piloted to ensure clarity and
understanding with three young adults (who were
diabetes service users) and one researcher. Within both
surveys, participants were shown the list of 87 outcomes,
grouped into seven domains for ease of survey comple-
tion: Lifestyle; Quality of life; Diabetes clinics; Medical;
Blood glucose; Treatment preferences in relation to
diabetes; and Intervention-related outcomes.
In survey 1, participants were asked to rate how import-
ant they considered each of the outcomes, on a scale of 1–
9, where 9 was the most important. Survey 1 included a
brief demographic questionnaire, in which respondents
provided information on: country of residence; gender;
whether they had been diagnosed with T1DM; and the
stakeholder group to which they belonged (young adults
with T1DM, diabetes health professionals, diabetes
researchers or people who inform policy on diabetes
services). As roles are not mutually exclusive, participants
could indicate that they belonged to more than one group.
Survey 1 was live for one month (from 29 April 2016 to 29
May 2016).
Four weeks after they completed Survey 1, all partici-
pants were followed up by email and invited to complete
Survey 2. In Survey 2, participants received information
about the average rating for each outcome by all partici-
pants in Survey 1 and a reminder of their own Survey 1
rating. Participants were asked to re-rate the importance
of each outcome with knowledge of their individual as
well as the groups’ previous ratings. The same Likert-type
rating scale in the range of 1–9 was used. Survey 2 closed
on 17 June 2016.
Phase 3: Consensus meeting
A 3-h consensus meeting was held in Galway, Ireland, in
June 2016 with the aim to agree on a final COS,
informed by ratings from the Delphi survey. Participants
for this meeting were sampled purposively to get a
balanced representation for each of the stakeholder
groups and a reasonable geographical spread. The sam-
ple was drawn from participants who had completed
both survey rounds. Survey 2 data were used to generate
discussion and move towards consensus. Before the
meeting, using Survey 2 data, each outcome was cate-
gorised as category A (high agreement and high
support), category B (low agreement and mixed support)
or category C (high agreement and low support). Category
C outcomes were excluded from further discussion and
were not considered for inclusion in the final COS. See
Table 1 for further detail of categorisation criteria.
The meeting was structured into three parts. First, re-
view and discussion of outcomes for which there had
been low agreement in survey 2 (category B outcomes).
These outcomes were discussed by domain and partici-
pants were asked to share their views with the group
about why they considered the outcome should, or
should not, be considered for inclusion in the final
decision-making discussion and voting. Second, re-
rating of category B outcomes on a paper survey, using
the same Likert-type rating scale in the range of 1–9.
These data were entered into a Microsoft Excel software
database at a computer within the room. Data were en-
tered by one person, and checked by a second. Those
outcomes which at least 70% of consensus group partici-
pants had rated as 8 or higher in the re-rating process,
were named ‘new category A outcomes’ and were
retained for inclusion in the final decision-making
discussion and voting phase. The final phase involved
the discussion and voting of category A outcomes for
inclusion in the final COS.
During this phase, all original category A outcomes
(from Survey 2) and new category A outcomes (from the
consensus meeting re-rating) were written onto large
sticky notes and posted on a wall in the room. Each out-
come was discussed in turn, followed by a vote (by
hand-raising) as to whether participants believed the
outcome should be included in the final COS. A mem-
ber of the research team recorded the number of votes
each outcome received on the sticky note.
Those outcomes voted for inclusion by at least 70% of
consensus group participants (≥9) were grouped
together and presented on a separate part of the wall
under the heading ‘final core outcome set’. After all out-
comes had been voted on, and the total COS was
reviewed, the group were given another opportunity to
comment on included items and indicate if they believed
the COS was comprehensive. Following this discussion,
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any outcomes which were discussed at this phase were
voted on and the same inclusion criteria were applied (i.e.
outcomes which at least 70% of consensus group partici-
pants voted for were retained in the final COS). Any cat-
egory A outcomes not included in the final COS, became
part of a list categorised as ‘supplementary outcomes’.
Results
Figure 1 shows a flowchart of the study methodology and
summarises outcomes at each phase. Details of Delphi sur-
vey participants (stakeholder group and gender) at rounds 1
(n= 132) and 2 (n = 81), as well as consensus meeting par-
ticipants (n= 12), can be seen in Table 2. Of the 12 people
who participated in the consensus meeting, eight were
women and four were men. The group included three
young adults with T1DM, four diabetes health professionals,
four diabetes researchers and one diabetes policy maker.
Participants were from Ireland (n = 8), Canada (n= 1),
Australia (n= 1), Singapore (n = 1) and Denmark (n= 1).
Outcome ratings at rounds 1 and 2 are summarised in
Additional file 2: Tables S1–S7. Based on the categorisa-
tion of Survey 2 data, the 87 outcomes were categorized
as follows: 23 category A outcomes; 63 category B out-
comes; and 0 category C outcomes (see Table 3).
Based on the discussion and re-rating of category B
outcomes during the consensus meeting, five category B
outcomes were re-categorised as ‘new category A out-
comes’. Three of these were deemed new category A
Table 1 Criteria for categorising outcomes based on Delphi Survey 2 data for the consensus meeting
Category Criteria required
Category A: High agreement and high support Rated by≥ 70% of participants as≥ 8
Category B: Low agreement and mixed support Rated by < 70% of participants as≥ 8 and rated by < 70% of participants scored as≤ 6
Category C: High agreement and low support Rated by≥ 70% of participants as≤ 6
Fig. 1 Flowchart of the study methodology
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outcomes as they had reached the consensus criteria on
re-rating. These were: ‘Number of missed clinic appoint-
ments’ (nine participants rated as 8+); ‘Number of events
of severe hypoglycaemia’ (11 participants rated as 8+);
and ‘Perceived level of control over diabetes’ (eight par-
ticipants rated as 8+). Two further items were included
as meeting participants argued strongly for their
inclusion. These were: ‘Body mass index (BMI)’; and
‘Perceived levels of barriers to treatment’. The group
agreed to allow these two additional variables to be
included in the ‘new category A outcomes’ list. The re-
rating data for these variables can be seen in Table 4.
The final phase of the consensus meeting, which was
the decision-making discussion and voting phase, lasted
for approximately 1 h. During this phase, 23 ‘original
category A outcomes’ and five ‘new category A outcomes’
Table 2 Details of participants in Delphi survey rounds 1 and 2 and consensus meeting (stakeholder group, gender and
country of residence)
Round 1 n (% of total) (n = 132) Round 2 n (% of total) (n = 81) Consensus meeting n (n = 12)
Stakeholder group
Young adults with T1DM 34 (25.8) 17 (21.0) 3
Diabetes researchers 30 (22.7) 24 (29.6) 4
Diabetes health professionals 76 (57.6) 49 (60.5) 4
Diabetes policy makers 2 (1.5) 1 (1.2) 1
Gender
Male 28 (21.2) 22 (27.2) 4
Female 104 (78.8) 59 (72.8) 8
Country of residence
Australia 1 (0.8) 1 (1.2) 1
Canada 6 (4.5) 6 (7.4) 1
Denmark 7 (5.3) 5 (6.2) 1
England 11 (14.5) 3 (3.7) -
Germany 2 (1.5) 1 (1.2) -
Ireland 64 (48.5) 40 (49.4) 8
N. Ireland 9 (6.8) 4 (4.9) -
Norway 1 (0.8) - -
Scotland 6 (4.5) - -
Singapore 1 (0.8) 1 (1.2) 1
Slovenia 1 (0.8) - -
Switzerland 1 (0.8) 1 (1.2) -
UK 19 (14.4) 18 (22.2) -
USA 2 (1.5) 1 (1.2) -
Wales 1 (0.8) - -
Table 3 Categorisation of outcomes by domain as A, B or C,a based on Delphi Survey 2 ratings
Domain Outcomes in category A (n) Outcomes in category B (n) Outcomes in category C (n)
Lifestyle 0 8 0
Quality of life 7 5 0
Diabetes clinics 0 10 0
Medical 5 6 0
Blood sugar 3 11 0
Treatment preferences in relation to diabetes 2 15 0
Intervention-related 6 8 0
Total 23 63 0
aCategory A: strong agreement and strong support; category B: low agreement and mixed support; category C: high agreement and low support. For further
details on category definitions, see Table 2
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were discussed and voted upon. Additional file 2: Table S8
shows levels of support for each of the ‘supplementary
important outcomes’, i.e. the category A outcomes that
were not voted for inclusion in the COS. The final list was
agreed through discussion: the names of some outcomes
were changed slightly to clarify the meaning, some out-
comes were collapsed together and assumed under one
outcome title and other outcomes were added. Outcomes
whose name was changed to clarify meaning included:
‘Measure of diabetes related burden’, which became ‘Meas-
ure of diabetes related burden and stress’; ‘Glycated
haemoglobin (HbA1c) measured by a researcher’ became
‘Objectively measured HbA1c’; ‘Number of missed clinic
appointments’ became ‘Level of clinic engagement’; and
‘Number of hospitalisations and readmissions for diabetic
ketoacidosis (DKA)’ was renamed as ‘Number of instances
of diabetic ketoacidosis (DKA)’. Two outcomes—‘Number
of events of severe hypoglycaemia’ and ‘Severity of events
of hypoglycaemia’—were discussed and participants
agreed that these could be subsumed under the one out-
come heading ‘Number of events of severe
hypoglycaemia’. The outcome ‘Quality of life’ was dis-
cussed and participants agreed that ‘Diabetes-related qual-
ity of life’ was more suitable as a core outcome, so this
outcome was included as an additional outcome and
voted upon.
When the final COS was presented and reviewed,
there was a strongly expressed view that the COS was
lacking some aspect of self-management behaviour.
Participants agreed to add this outcome (‘Self-manage-
ment behaviour’) and it was voted to be included in the
final COS.
Table 5 shows levels of support for each outcome in
the final COS, containing eight outcomes: measures of
diabetes-related burden or stress; diabetes-related quality
of life; number of severe hypoglycaemic events; self-
management behaviour; number of instances of diabetic
ketoacdidosis (DKA); objectively-measured glycated
haemoglobin (HbA1C); level of clinic engagement; and
perceived level of control over diabetes.
Discussion
This is the first attempt to produce a COS for interven-
tion trials aiming to improve clinical, behavioural or psy-
chosocial outcomes for young adults (aged 15–30 years)
with T1DM. We sought the views of an international
sample of young adults with T1DM, diabetes health pro-
fessionals, diabetes researchers and people who inform
policy on diabetes in a Delphi consensus process and
agreed a final COS containing eight outcomes: measures
of diabetes-related burden or stress; diabetes-related
quality of life; number of severe hypoglycaemic events;
self-management behaviour; number of instances of
diabetic ketoacdidosis (DKA); objectively-measured gly-
cated haemoglobin (HbA1C); level of clinic engagement
and perceived level of control over diabetes. We suggest
that future research evaluating interventions in T1DM
should assess and report these outcomes. As with all
COS, these outcomes are proposed to be included as a
minimum, but additional outcomes may be included as
appropriate to different interventions and settings.
Our COS covers a broad range of aspects of diabetes,
including stress, quality of life, medical or biological
Table 4 Re-rating data for ‘new category A’ outcomesa (i.e. outcomes which were later included in the voting for inclusion phase)
during the consensus meeting
Outcome name Number rating outcome measure 8 or higher (n = 12) Mean rating Standard deviation
Body mass index (BMI)b 3 6.33 2.06
Missed clinic appointments (n) 9 7.75 1.36
Events of severe hypoglycaemia (n) 11 8.67 0.65
Perceived levels of barriers to treatmentb 7 6.83 2.04
Perceived level of control over diabetesc 8 7.50 2.28
aNew category A outcomes are those outcomes categorised as outcome B based on Delphi Survey 2 ratings, but subsequently received sufficient support through
discussion and re-rating at the consensus meeting to warrant their inclusion in the set of outcomes voted on for inclusion in the final COS
bWhile the outcome ‘BMI’ was well below the cut-off for inclusion as a new category A outcome, one participant argued passionately for its inclusion and
subsequently consensus group participants agreed for its inclusion in the voting phase
cWhile this variable was one vote below the cut-off for inclusion as a new category A outcome, a number of participants argued for its inclusion in the voting
phase and consensus group participants agreed
Table 5 Final COS with level of support in the final voting
phase
Outcome n voting for inclusion of outcome in
the final COS (n = 12)
1. Measures of diabetes-related
burden or stress
12
2. Diabetes-related quality of life 12
3. Number of events of
severe hypoglycaemia
11
4. Self-management behaviour 11
5. Number of instances of diabetic
ketoacdidosis (DKA)
10
6. Objectively measured glycated
haemoglobin (HbA1c)
10
7. Level of clinic engagement 9
8. Perceived level of control
over diabetes
9
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markers, self-management behaviour, level of engage-
ment with health services and diabetes management.
The fact that stress and quality of life were ranked
during the consensus process as more important than
measures of metabolic control (such as glycated haemo-
globin), supports previous research which has empha-
sised the need to broaden the types of measures which
are traditionally used [19, 20]. Selecting outcomes based
on the consensus methods we have used provides a
more evidence-based approach to outcome selection
than methods generally used, such as simply measuring
what has been measured in previous research [21].
Future research is now needed to identify the most ap-
propriate outcome measures for each of these outcomes.
Recent guidance has been published offering guidance
on this process [22].
These strengths notwithstanding, the present study is
not without its limitations. Although Delphi processes
have been recommended as an ideal approach to identify
which outcomes to measure in clinical trials [21], they
have also been criticised regarding the ambiguities which
exist around the issue of defining consensus and expert-
ise [23]. While the study aimed to have a reasonably
balanced number of participants from all stakeholder
groups, this did not prove possible. Policy makers and
young adults with T1DM were difficult to recruit and
were under-represented in the study. Furthermore, it is
possible that the young adult participants were not
representative of all young adults, as they are likely to be
more active in acquiring information about T1DM and
therefore more engaged. Although we attempted to
achieve an international sample in our study, the sample
came largely from English-speaking countries, predom-
inantly Ireland. We must use caution in claiming the
international generalisability of these findings, especially
as non-English-speaking and developing countries are
under-represented; future research would be useful to
test the international relevance of the outcomes identi-
fied as core within our study. Another limitation of the
study is that by utilising mailing lists and social media to
recruit participants it was impossible to calculate the
recruitment rate for the study. The reasonably high level
of attrition between rounds 1 and 2 of the study also
limits the validity of the study. The final consensus
meeting was only open to a small number of partici-
pants, again limiting generalisability of the findings. In
addition, social and peer pressures may have influenced
voting behaviour of consensus group participants, as
voting was public involving raising hands to indicate
support for outcomes.
Conclusion
In conclusion, albeit with limitations, this study was an
important attempt to identify a COS for intervention
research for young adults with T1DM. It provides guid-
ance about what outcomes are important to young adults
with T1DM and other key stakeholders. We sought the
views of a sample of young adults with T1DM, diabetes
health professionals, diabetes researchers and policy
makers in diabetes services. This COS will be useful for
future intervention trials in this area, encouraging a more
coordinated approach to intervention research in the
future than currently exists and facilitating more meaning-
ful synthesis of research findings. It is worth noting that
any COS identified is a dynamic, rather than fixed, entity,
which will evolve as research is conducted. Future
research is needed to replicate the findings from this COS
study, in particular testing its international generalisability,
and to determine and provide guidance on the best out-
come measures to select to measure these variables.
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